Home » Parkinson’s disease

Articles Tagged with ''Parkinson’s disease''

NRG closes £16M series A to fund fight against neurodegenerative diseases

Nov. 15, 2022

NRG Therapeutics Ltd. has closed a £16 million (US$18.3 million) series A round to take forward programs in Parkinson’s disease and amyotrophic lateral sclerosis, after pinning down the target of its brain penetrant small molecules.

Neurology/Psychiatric

Chinese researchers patent new CFB inhibitors for Parkinson's disease

Nov. 11, 2022

No Comments

Medshine Discovery Inc. and Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. have disclosed bicyclic substituted aromatic carboxylic acid compounds acting as complement factor B (CFB) inhibitors reported to be useful for the treatment of Parkinson's disease.

NRG closes £16M series A to fund fight against neurodegenerative diseases

Nov. 9, 2022

By Nuala Moran

No Comments

Neurology/Psychiatric

Neuropn Therapeutics presents bifunctional epoxide hydrolase 2 inhibitors for Parkinson's disease

Nov. 9, 2022

No Comments

Neuropn Therapeutics LLC has divulged piperidine urea derivatives as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of Parkinson's disease, pain, inflammation and neurodegeneration.

Neurology/Psychiatric

Nkgen Biotech collaborates with Parkinson's Foundation to advance SNK-01 toward clinic for Parkinson's

Nov. 7, 2022

No Comments

Nkgen Biotech Inc. has established a...

Neurology/Psychiatric

Shandong Luye Pharmaceutical presents new compounds for Parkinson’s disease

Nov. 2, 2022

No Comments

Shandong Luye Pharmaceutical Co. Ltd. has divulged cannabidiol prodrugs reported to be useful for the treatment of cancer, tremor, epilepsy, anxiety disorder, inflammatory disorders, pain, multiple sclerosis and Parkinson's disease, among others.

Neurology/Psychiatric

Novel mPGES-1 inhibitor demonstrates neuroprotective effects in models of PD

Oct. 21, 2022

No Comments

mPGES-1 is overexpressed in the dopaminergic neurons of the substantia nigra pars compacta of post-mortem brain tissue from patients with Parkinson’s disease (PD) as well as in 6-hydroxydopamine (6-OHDA)-injected PD mice.

Neurology/Psychiatric

Lucy Therapeutics validates new mitochondrial-based therapeutic approach for Parkinson's disease

Oct. 14, 2022

No Comments

Lucy Therapeutics Inc. has announced promising preclinical data for multiple compounds in its lead program for Parkinson's disease, including two lead small-molecule agents, LucyTx-1209 and LucyTx-1212.

Neurons derived from human embryonic stem cells.

Neurology/Psychiatric

RS-79948 unveiled as a dopamine D2 receptor inhibitor

Oct. 4, 2022

No Comments

For a long time, α2-adrenoceptor antagonists have been successfully used as adjunct therapy to improve pharmacotherapy of antipsychotics, antidepressants or anti-parkinsonian drugs.

Parkinson's disease illustration showing neurons containing alpha-synuclein

Neurology/Psychiatric

Itanapraced reduces LRRK2 expression and results in neuroprotection in models of PD

Oct. 4, 2022

No Comments

Leucine-rich repeat kinase 2 (LRRK2) mutations adversely impair multiple physiological processes, and gain-of-function mutations in the LRRK2 gene are common in familial forms of Parkinson’s disease (PD).

Today's news in brief
BioWorld
BioWorld briefs for Nov. 27, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 27, 2024.
In muscular dystrophies, gene therapies race the clock
BioWorld
Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...
Bridgebio, with FDA approval, faces Pfizer in ATTR
BioWorld
With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...
‘Evo’ AI can design complete genomes
BioWorld Science
The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.